A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (NCT04853251)

🧪 Interventions in This Study

• PDS Implant With Ranibizumab 100 mg/ml (DEVICE)
• LUCENTIS (Ranibizumab Injection) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (52 Sites)

Showing the first 25 of 52 sites.

• Barnet Dulaney Perkins Eye Center — Mesa, Arizona
• California Retina Consultants — Bakersfield, California
• Retina Associates of Southern California — Huntington Beach, California
• California Eye Specialists Medical group Inc. — Pasadena, California
• Retinal Consultants Med Group — Sacramento, California
• University of California San Francisco — San Francisco, California
• Orange County Retina Med Group — Santa Ana, California
• Macula Retina Vitreous Research Institute — Torrance, California
• Southwest Retina Consultants — Durango, Colorado
• Advanced Vision Research Institute — Longmont, Colorado
• Retina Group of New England — Waterford, Connecticut
• Retina Specialty Institute — Pensacola, Florida
• Ft Lauderdale Eye Institute — Plantation, Florida
• Retina Vitreous Associates of Florida — St. Petersburg, Florida
• Southeast Retina Center — Augusta, Georgia
• University Retina and Macula Associates, PC — Lemont, Illinois
• Wolfe Eye Clinic — West Des Moines, Iowa
• Retina Associates of Kentucky — Lexington, Kentucky
• Maine Eye Center — Portland, Maine
• The Retina Care Center — Baltimore, Maryland
• Wilmer Eye Institute Johns Hopkins University — Baltimore, Maryland
• Retina Group of Washington — Chevy Chase, Maryland
• Cumberland Valley Retina Consultants PC — Hagerstown, Maryland
• Associated Retinal Consultants PC — Royal Oak, Michigan
• VitreoRetinal Surgery, PLLC. — Minneapolis, Minnesota

📞 Contact the Study Coordinator

Phone: (888) 662-6728

Email: global-roche-genentech-trials@gene.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Neovascular Age-related Macular Degeneration

• A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) — Arcadia, California
• A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration — Phoenix, Arizona
• Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) — Beverly Hills, California
• Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — Gilbert, Arizona
• Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD — Glendale, California
• Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] — Phoenix, Arizona

Explore by condition: All Neovascular Age-related Macular Degeneration clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.